|
[1]
|
Witjes, J.A., Bruins, H.M., Cathomas, R., et al. (2021) European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. European Urology, 79, 82-104. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Kamat, A.M., Hahn, N.M., Efstathiou, J.A., et al. (2016) Bladder Cancer. The Lancet (London, England), 388, 2796- 2810. [Google Scholar] [CrossRef]
|
|
[4]
|
Knowles, M.A. and Hurst, C.D. (2015) Molecular Biology of Bladder Cancer: New Insights into Pathogenesis and Clinical Diver-sity. Nature Reviews. Cancer, 15, 25-41. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Stein, J.P., Lieskovsky, G., Cote, R., et al. (2001) Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 19, 666-675. [Google Scholar] [CrossRef]
|
|
[6]
|
Madersbacher, S., Hochreiter, W., Burkhard, F., et al. (2003) Radical Cystectomy for Bladder Cancer Today—A Homogeneous Series without Neoadjuvant Therapy. Journal of Clin-ical Oncology: Official Journal of the American Society of Clinical Oncology, 21, 690-696. [Google Scholar] [CrossRef]
|
|
[7]
|
Lopez-Beltran, A., Cimadamore, A., Blanca, A., et al. (2021) Im-mune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers, 13, 131. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Sharma, P., Retz, M., Siefker-Radtke, A., et al. (2017) Nivolumab in Metastatic Urothelial Carcinoma after Platinum Therapy (CheckMate 275): A Multicentre, Single-Arm, Phase 2 Trial. The Lancet. Oncology, 18, 312-322. [Google Scholar] [CrossRef]
|
|
[9]
|
Mariathasan, S., Turley, S.J., Nickles, D., et al. (2018) TGFβ Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells. Nature, 554, 544-548. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Yang, L., Hong, S., Wang, Y., et al. (2016) A Novel Prognostic Score Model Incorporating CDGSH Iron Sulfur Domain2 (CISD2) Predicts Risk of Disease Progression in Laryngeal Squa-mous Cell Carcinoma. Oncotarget, 7, 22720- 22732. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Yeh, C.-H., Shen, Z.-Q., Hsiung, S.-Y., et al. (2019) Cisd2 Is Essential to Delaying Cardiac Aging and to Maintaining Heart Func-tions. PLoS Biology, 17, e3000508. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Sun, A.-G., Meng, F.-G. and Wang, M.-G. (2017) CISD2 Promotes the Proliferation of Glioma Cells via Suppressing Beclin-1-Mediated Au-tophagy and Is Targeted by microRNA‑449a. Molecular Medicine Reports, 16, 7939-7948. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Sun, Y., Jiang, Y., Huang, J., et al. (2017) CISD2 Enhances the Chemosensitivity of Gastric Cancer through the Enhancement of 5-FU-Induced Apoptosis and the Inhibition of Autoph-agy by AKT/mTOR Pathway. Cancer Medicine, 6, 2331-2346. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Wang, C.-H., Chen, Y.-F., Wu, C.-Y., et al. (2014) Cisd2 Modulates the Differentiation and Functioning of Adipocytes by Regulating Intracellular Ca2+ Homeostasis. Human Molecular Genetics, 23, 4770-4785. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Zhu, Q.-Q., Tian, L., Li, D.-L., et al. (2020) Elevated CISD2 Expression Predicts Poor Diagnosis and Promotes Invasion and Migration of Prostate Cancer Cells. European Review for Medical and Pharmacological Sciences, 24, 6597- 6604.
|
|
[16]
|
Mozzillo, E., Delvecchio, M., Carella, M., et al. (2014) A Novel CISD2 Intragenic Deletion, Optic Neuropathy and Platelet Aggregation Defect in Wolfram Syndrome Type 2. BMC Medical Genetics, 15, 88. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Liu, L., Xia, M., Wang, J., et al. (2014) CISD2 Expression Is a Novel Marker Correlating with Pelvic Lymph Node Metastasis and Prognosis in Patients with Early-Stage Cervical Can-cer. Medical Oncology (Northwood, London, England), 31, 183. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Chen, B., Shen, S., Wu, J., et al. (2015) CISD2 Associated with Proliferation Indicates Negative Prognosis in Patients with Hepatocellular Carcinoma. International Journal of Clinical and Experimental Pathology, 8, 13725-13738.
|
|
[19]
|
Wang, L., Ouyang, F., Liu, X., et al. (2016) Overexpressed CISD2 Has Prognostic Value in Human Gastric Cancer and Promotes Gastric Cancer Cell Proliferation and Tumorigenesis via AKT Signaling Pathway. Oncotarget, 7, 3791-3805. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Li, S.-M., Chen, C.-H., Chen, Y.-W., et al. (2017) Upregulation of CISD2 Augments ROS Homeostasis and Contributes to Tumorigenesis and Poor Prognosis of Lung Adenocarcinoma. Scientific Reports, 7, Article No. 11893. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Chen, Y.-F., Wu, C.-Y., Kirby, R., et al. (2010) A Role for the CISD2 Gene in Lifespan Control and Human Disease. Annals of the New York Academy of Sciences, 1201, 58-64. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Kim, E.H., Shin, D., Lee, J., et al. (2018) CISD2 Inhibition Overcomes Resistance to Sulfasalazine-Induced Ferroptotic Cell Death in Head and Neck Cancer. Cancer Letters, 432, 180-190. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
刘璐欣, 何勉, 刘军秀, 等. CISD2在早期宫颈腺癌中的表达和临床意义[J]. 中山大学学报(医学科学版), 2015, 36(5): 728-733.
|
|
[24]
|
刘壮凯, 白静慧, 张瑞山, 等. CISD2在乳腺癌组织中的表达及其对人乳腺癌MCF-7细胞增殖与侵袭的影响[J]. 解剖科学进展, 2020, 26(2): 140-142.
|